The New Supplementary Contribution & A Return of the "M" Contribution to its Original Intent One of the most consequential structural changes in PLFSS 2026 concerns how the French system manages spending overruns. For years, the Safeguard Clause (clause de sauvegarde, or "clause M") served as the primary cost-control backstop but it was criticized for unpredictability and its repeated activation had stripped it of any "exceptional" character. The system has been reshaped with

Written by TruBio Consulting, LCC on March 18, 2026 Driven by converging pressures such as industry push back on skyrocketing rebates, geopolitical trade dynamics, and patient access delays, England has introduced sweeping changes to market access and reimbursement policies for the first time in years, even decades. Below, we break down the 2026 changes to England's market access & reimbursement landscape. The MHRA-NICE Aligned Pathway The most structurally significant chang

BMS, Pfizer, and AstraZeneca each made bold moves this week that signal how pharma is evolving. From deep direct-to-patient discounts and billion-dollar bets on obesity to a Supreme Court fight over Medicare pricing, the industry is rewriting its playbook. Access, affordability, and innovation are at the center of what comes next.

This week’s pharma headlines highlight a shifting competitive landscape: J&J’s psoriasis pill icotrokinra challenges biologics, Novo Nordisk’s Rybelsus secures a first-in-class EU cardiovascular label, and GSK commits $30B to U.S. expansion under political pressure.